RecruitingLabral Tear, GlenoidFemoral Acetabular Impingement
Blood Flow Restriction Following Hip Arthroscopy
Eligible age
18–40 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.
Sponsor: Rush University Medical Center
You may qualify if…
- ✓ Adult patients 18-40
- ✓ English-speaking
- ✓ Clinical and radiographic examination (MRI) consistent FAIS and/or labral pathology, and are schedule for primary hip arthroscopy
- ✓ Written and informed consent for study participation
You may not qualify if…
- ✕ Patients younger than 18 or older than 40 years of age
- ✕ Non-native English speaker
- ✕ Revision surgery or prior history of ipsilateral hip or knee surgery
- ✕ Inability to comply with the proposed follow-up clinic visits
- ✕ Patients lacking decisional capacity
- ✕ Patients with a history of deep vein thrombosis, pulmonary embolism, or known clotting disorder or hypercoagulable state
- ✕ Pregnant or breast-feeding women. Pregnancy as determined by a positive pregnancy test prior to procedure. Females of childbearing potential must agree to use an acceptable birth control method during study participation.
- ✕ Worker's compensation patients
Where it's recruiting
Illinois
Chicago
Source: ClinicalTrials.gov · NCT04113759 · last updated 2025-12-05